EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Empagliflozin and Metformin Combination Therapy Attenuates Oxidative Stress and Inflammation in Experimental Cardio–Kidney–Metabolic Syndrome

Fernando Cortes-Camacho, Oscar R Zambrano-Vásquez iD, Fernando E García-Arroyo, Elena Aréchaga-Ocampo, Jorge I Castañeda-Sánchez iD, Daniel Manzur-Sandoval, Francisco Javier Roldan-Gómez, Leonardo Del Valle-Mondragón iD, O Emiliano Aparicio-Trejo, Constanza E Martínez-Olivares iD, Rogelio Hernández-Pando iD, José G Gonzaga-Sánchez und 2 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27208988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Fernando Cortes-Camacho und 13 weiteren Autor:innen. Beteiligte Einrichtung: Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City 04960, Mexico. Hauptthemen laut MEDLINE: Oxidative Stress, Metabolic Syndrome, Benzhydryl Compounds, Metformin. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Nacional de Cardiología Ignacio Chávez.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the therapeutic effects of the empagliflozin+metformin (E+M) combination on cardio–kidney–metabolic syndrome (CKMS) using an experimental model. Animals were fed a Paigen-type (high-fat) diet supplemented with sugar-sweetened beverages to induce the CKMS phenotype. After confirming metabolic, cardiovascular, and renal alterations, animals were randomized into untreated and E+M-treated groups for 30 days while continuing the diet. Cardiovascular risk factors, vasoactive substances in the heart and kidney, oxidative stress, and the expression of inflammatory markers and the lipogenic transcription factors ChREBP and SREBP1 were analyzed. The E+M combination reduced body weight, hyperglycemia, fasting glucose, and hypertension, while restoring the lipid profile and improving oral glucose tolerance and renal function (p < 0.05). It also reduced posterior wall and interventricular septal thickening, as well as the elevated septum/posterior wall (PP/PS) ratio observed in the CKMS group (p < 0.05). Likewise, the increases in angiotensin II and nitric oxide concentrations in the hearts and kidneys were attenuated (p < 0.05). The CKMS group exhibited glomerular hypertrophy and reduced total antioxidant capacity mitochondrial complex I and II activities, glutathione peroxidase, glutathione reductase, and superoxide dismutase activities, and Nrf2 and IL-10 expression, all of which were restored by combination therapy (p < 0.05). In contrast, the upregulation of IGF-1, aldose reductase, sorbitol dehydrogenase, ChREBP, IL-6, TNFα, and NF-κB observed in the CKMS group was reduced following E+M treatment (p < 0.05). Overall, the E+M combination attenuated metabolic alterations and suppressed renal oxidative stress and inflammation, providing cardiac and renal protection at both functional and structural levels. These effects appear to be mediated by the modulation of key proteins involved in vascular tone, uric acid metabolism, oxidative stress, inflammation, and regulation of transcription factors involved in carbohydrate and lipid metabolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oxidative StressMetabolic SyndromeBenzhydryl CompoundsMetforminGlucosidesInflammationCardiovascular DiseasesKidney DiseasesAnimalsMaleKidneyDrug Therapy, CombinationRatsDisease Models, Animal

Stichwörter der Autor:innen

cardiovascular riskempagliflozinhypertensionhyperuricemiainflammationmetabolic risk factorsmetforminoxidative stressrenal dysfunction

Substanzen

empagliflozinBenzhydryl CompoundsMetforminGlucosides

Autor:innen und Institutionen

  • Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City 04960, Mexico.
  • Departamento de Fisiopatología Cardio-Renal, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.
  • Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana, Unidad Cuajimalpa, Mexico City 05348, Mexico.
  • Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana, Unidad Xochimilco, Mexico City 04960, Mexico.
  • Cardiovascular Critical Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.
  • Outpatient Department, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.

ORCID-Profile: Oscar R Zambrano-Vásquez, Jorge I Castañeda-Sánchez, Leonardo Del Valle-Mondragón, Constanza E Martínez-Olivares, Rogelio Hernández-Pando, Horacio Osorio-Alonso

Förderung

  • Instituto Nacional de Cardiología Ignacio Chávez

Zitieren

APA

Cortes-Camacho, F., Zambrano-Vásquez, O. R., García-Arroyo, F. E., Aréchaga-Ocampo, E., Castañeda-Sánchez, J. I., Manzur-Sandoval, D., Roldan-Gómez, F. J., Valle-Mondragón, L. D., Aparicio-Trejo, O. E., Martínez-Olivares, C. E., Hernández-Pando, R., Gonzaga-Sánchez, J. G., Sánchez-Lozada, L. G., & Osorio-Alonso, H. (2026). Empagliflozin and Metformin Combination Therapy Attenuates Oxidative Stress and Inflammation in Experimental Cardio–Kidney–Metabolic Syndrome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27208988

Vancouver

Cortes-Camacho F, Zambrano-Vásquez OR, García-Arroyo FE, Aréchaga-Ocampo E, Castañeda-Sánchez JI, Manzur-Sandoval D, et al. Empagliflozin and Metformin Combination Therapy Attenuates Oxidative Stress and Inflammation in Experimental Cardio–Kidney–Metabolic Syndrome. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27208988

BibTeX
@article{CortesCamacho2026,
  author = {Cortes-Camacho, Fernando and Zambrano-Vásquez, Oscar R and García-Arroyo, Fernando E and Aréchaga-Ocampo, Elena and Castañeda-Sánchez, Jorge I and Manzur-Sandoval, Daniel and Roldan-Gómez, Francisco Javier and Valle-Mondragón, Leonardo Del and Aparicio-Trejo, O Emiliano and Martínez-Olivares, Constanza E and Hernández-Pando, Rogelio and Gonzaga-Sánchez, José G and Sánchez-Lozada, Laura G and Osorio-Alonso, Horacio},
  title = {Empagliflozin and Metformin Combination Therapy Attenuates Oxidative Stress and Inflammation in Experimental Cardio–Kidney–Metabolic Syndrome},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27208988}
}
Kostenlos starten →